PCDH7

Across TCGA pan-cancer cohorts, PCDH7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCDH7 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCDH7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDH7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where PCDH7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.300	0.593	.001	20	view →
HNSC	DFS	Tertile	III,IV	1.000	0.900	.041	4	view →
UCEC	OS	Median	All	0.991	0.908	.029	2	view →
LSCC	DFS	Quartile	All	0.373	1.000	.026	2	view →
GBM	DFS	Quartile	All	0.885	0.637	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCDH7–PDAC (DFS)

Open the PDAC breakdown →